Jenny Vu Pozadzides, M.D.
Department of General Oncology, Division of Cancer Medicine
About Dr. Jenny Vu Pozadzides
Dr. Pozadzides earned her medical degree from The University of Texas Medical School, where she also completed her residency in Internal Medicine. She completed two fellowships in Hematology and Medical Oncology at MD Anderson Cancer Center. Dr. Pozadzides has authored and co-authored numerous articles in peer-reviewed journals on cancer-related topics, and has taken part in several MD Anderson research projects. She frequently lectures at local, regional and national education events and serves on various committees at MD Anderson and local hospitals. She is a collaborator in many clinical trials that are available in The Woodlands where she offers her patients personalized care. Dr. Pozadzides won the 2012 Janice David Singletary Fellowship for Lymphoma Award at MD Anderson and a 2011 Abstract Achievement Award from the American Society of Hematology for her scholarly work. The doctor participates in multidisciplinary conferences and gives input weekly in patient-focused conferences. She is active in The Woodlands and Houston cancer prevention and volunteer community. She has participated in many community outreach programs and also mentors high school students. Community service is an important part of her life and she believes in giving back and helping those who are in need. Dr. Pozadzides prides herself on getting to know her patients and their family on a personal level. Further, she works hard to educate, inspire and bring together those touched by cancer. Dr. Pozadzides understands that cancer doesn't just affect the body, but also our families, work life, psychology, personal finances and so much more. Together with her husband and three daughters, Dr. Pozadzides lives in The Woodlands. She is Vietnamese and her husband is Greek. They love to travel and have been to a few continents. She loves to get to know people from different backgrounds and teaches her children to do the same.
Present Title & Affiliation
Primary Appointment
Professor (Joint appointment), Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Patient Experience Officer, The University of Texas MD Anderson Cancer Center, The Woodlands, TX
Education & Training
Degree-Granting Education
| 2005 | The University of Texas Medical School-Houston, Houston, Texas, US, MD |
| 2000 | The University of Texas at Austin, Austin, Texas, US, Biology, BA |
Postgraduate Training
| 2009-2012 | Hematology and Medical Oncology Fellowship, Hematology and Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2007-2009 | Residency in Internal Medicine, Internal Medicine, The University of Texas - Houston, Houston, Texas |
| 2006-2007 | Research Fellowship, T-Cell Lymphoma Research Fellowship, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2005-2006 | Internship in Internal Medicine, Internal Medicine, The University of Texas - Houston, Houston, Texas |
Licenses & Certifications
| 2022 | Florida Board of Medicine |
| 2018 | BLS |
| 2017 | Texas Medical License |
| 2013 | DEA |
| 2012 | Medical Oncology Board Certified |
| 2012 | Hematology Board Certified |
| 2009 | Internal Medicine Board Certified |
Experience & Service
Faculty Academic Appointments
Associate Professor, Thoracic-Head & Neck Med Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2020 - 2024
Associate Professor, General Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2018 - 2024
Assistant Professor, General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2018
Clinical Specialist, General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2009 - 2012
Administrative Appointments/Responsibilities
Mentoring Connector, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2025 - Present
Member, Executive Committee of Faculty Senate, The University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - 2023
Faculty Senator, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2019 - 2025
Patient Experience Officer, The University of Texas MD Anderson Cancer Center, The Woodlands, Texas, 2018 - Present
Extramural Institutional Committee Activities
Member, MDACC General Oncology Department Chair Search Advisory Committee, The University of Texas MD Anderson Cancer Center, 2025 - 2025
Member, MDACC Critical Care Medicine Department Chair Search Committee, The University of Texas MD Anderson Cancer Center, 2025 - 2025
Member, MDACC Clinical IOTOX Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present
Member, MDACC Credentials Committee of the Medical Staff, The University of Texas MD Anderson Cancer Center, 2023 - 2026
Wellness Champion, MDACC Department of Cancer Medicine Wellness Champion, The University of Texas MD Anderson Cancer Center, 2023 - Present
Member, MDACC Executive Committee Faculty Senate Communication Task Force, The University of Texas MD Anderson Cancer Center, 2022 - 2025
Member, MDACC Executive Committee Faculty Senate Policy Review Task Force, The University of Texas MD Anderson Cancer Center, 2021 - 2025
Member, MDACC One MDA Working Group, The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, MDACC Executive Committee Faculty Senate Faculty Welfare Committee, The University of Texas MD Anderson Cancer Center, 2021 - 2025
Member, MDACC Executive Committee Faculty Senate, The University of Texas MD Anderson Cancer Center, 2021 - 2023
Member, MDACC Thoracic Enterprise Scheduling Committee, The University of Texas MD Anderson Cancer Center, 2020 - Present
Member, MDACC HALs Expansion Operations Committee, The University of Texas MD Anderson Cancer Center, 2020 - Present
Chair, MDACC The Woodlands HALs Tumor Board and Journal Club, The University of Texas MD Anderson Cancer Center, 2019 - 2021
Chair, MDACC General Oncology Grand Rounds, The University of Texas MD Anderson Cancer Center, 2018 - Present
Member, MDACC Transfusion and Patient Blood Management Committee, The University of Texas MD Anderson Cancer Center, 2017 - 2024
Member, MDACC Patient Experience Committee TMC, The University of Texas MD Anderson Cancer Center, 2017 - Present
Member, MDACC Patient Experience Committee the Woodlands, The University of Texas MD Anderson Cancer Center, 2017 - Present
Member, MDACC People We Serve: Faculty Vetting Committee, The University of Texas MD Anderson Cancer Center, 2015 - 2016
Expert Advisor (OEA), MDACC Champion for Lung Cancer in collaboration with IBM, The University of Texas MD Anderson Cancer Center, 2015 - 2016
Member, St. Luke's Quality of Care Committee, CHI St. Luke's The Woodlands Hospital, 2014 - 2019
Member, St. Luke's Pharmacy and Therapeutics Committee, CHI St. Luke's The Woodlands Hospital, 2014 - 2019
Member, MDACC Clinical Research Committee, The University of Texas MD Anderson Cancer Center, 2013 - 2014
Member, MDACC Regional Care Center Clinical Research Committee, The University of Texas MD Anderson Cancer Center, 2012 - 2015
Teaching Assistant, MDACC Communication Skills Curriculum Committee, The University of Texas MD Anderson Cancer Center, 2010 - 2012
Member, MDACC Institutional Review Board, The University of Texas MD Anderson Cancer Center, 2009 - 2012
Contributor, St. Luke's Quarterly Staff Meetings, CHI St. Luke's The Woodlands Hospital
Contributor, St. Luke's Multidisciplinary Conference, CHI St. Luke's The Woodlands Hospital
Contributor, MDACC The Woodlands HALs Breast Medical Oncology Multidisciplinary Conference, The University of Texas MD Anderson Cancer Center
Honors & Awards
| 2025 | MDACC Patient Experience Award: Top 10% Provider for 2025, MD Anderson Cancer Center |
| 2024 | MDACC Patient Experience Award: Top 1% Provider for FY24, MD Anderson Cancer Center |
| 2021 | MDACC Patient Experience Award: Top 10% Provider |
| 2020 - 2021 | Top Doctor Award |
| 2020 | Nominee for Melvin L. Samuels Award for Excellence in Patient Care, 15th Annual DOCM Faculty Recognition & Awards Program |
| 2020 | Top Medical Oncology Research Accrual Physician for HAL |
| 2019 - 2020 | MDACC Patient Experience Award: Top 1% Provider |
| 2013 - 2015 | Super Doctors Texas Rising Stars |
| 2012 | The Janice Davis Singletary Fellowship for Lymphoma Award |
| 2011 | ASH Abstract Achievement Award |
| 2005 - 2006 | Intern of the Year in Internal Medicine |
| 2003 | Recipient of the Medical School Outstanding Community Service Award from the Office of Community and Educational Outreach |
| 2002 | Recipient of the Medical School Committee on the Status of Women Scholarship for returning to London |
| 2002 | Recipient of the Medical School Scholarship for the London Research Project in antimicrobial resistance |
| 1999 - 2000 | Voted as Habitat for Humanity Campus Chapter Best Financial Officer |
| 1999 | National Keystone Honors Society |
| 1997 - 2000 | University of Texas at Austin Honors |
Professional Memberships
Selected Presentations & Talks
Regional Presentations
- 2008. Hydrochlorothiazide as a Putative Risk Factor for Cutaneous T-cell Lymphoma. Invited. Houston, TX, US.
- 2002. MRSA Bacteremia Surveillance and Infection Control. Invited. Houston, TX, US.
National Presentations
- 2007. Association of Polio and Skin Cancer. Invited. 65th Annual Meeting. Washington, DC, US.
- 2006. Dermatofibromas in a Patient of Mycosis Fungoides-Are They Related to Immunosuppression. Invited. 43rd Annual Meeting. Chicago, IL, US.
- 2006. Necrotizing Granulomatous Dermatitis and Panniculities Masquerading as T-Cell Lymphoma. Invited. 43rd Annual Meeting. Chicago, IL, US.
International Presentations
- 2002. MRSA Bacteremia Surveillance and Infection Control in Southeast England. Invited. London, GB.
Formal Peers
- 2006. Common Variable Immunodeficiency Syndrome associated with Epidermodysplasia Verriciformis. Visiting. San Antonio, TX, US.
- 2006. Mycosis Fungoides Tumor Stage. Visiting. Houston, TX, US.
- 2005. Hydrochlorothiazide as a putative risk factor for CTCL. Visiting. Los Angeles, CA, US.
Selected Publications
Peer-Reviewed Articles
- Zhang, B, Shah, K, Parma, M, Wang, K, Singhi, EK, Lewis, WE, Rivera, MJ, Altan, M, Pozadzides, JV, Le, X, Vokes, N, Fossella, FV, O'Brien, BJ, Wang, C, Tom, MC, Beckham, TH, Swanson, T, Bronk, JK, Lin, SH, Vega, MF, Jacome, J, Halliday, A, Vailati Negrao, M, Zhang, J, Gibbons, DL, Heymach, JV, Byers, LA, Gay, CM. Rapid Intracranial Response With Tarlatamab in Patients With Untreated Brain Metastases from SCLC—A Real-World Case Series. Journal of Thoracic Oncology 20(8):1131-1138, 2025. e-Pub 2025. PMID: 40126456.
- Paula AG, Liu X, Karimi A, Concannon K, Heeke S, Elamin YY, Wang K, Pozadzides JV, Vokes N, Tu J, Tsao A, Negrao MV, Zhang J, Singhi E, Zhang B, Rinsurongkawong W, Tran H, Gibbons D, Nilsson M, Heymach JV. Chemotherapy Plus a RET Inhibitor is Associated with Survival Benefit After Progression During a RET Inhibitor Treatment in a RET Fusion–Positive Non–Small Cell Lung Cancer Real-World Cohort: A Brief Report. JTO Clin Res Rep. e-Pub 2025.
- Vu Pozadzides J. Real-World Experience of Tarlatamab in Extensive-Stage Small Cell Lung Carcinoma showed Promising Systemic and Intracranial Efficacy with Higher Neurologic Toxicity. J Thorac Oncol. e-Pub 2025.
- Pan K, Owens J, Elamin Y, Lu C, Routbort M, Zhang J, Fossella F, Negrao MV, Altan M, Pozadzides J, Skoulidis F, Tsao A, Cascone T, Heymach JV, Ostrin E, Le X. Mutational Characteristics and Clinical Outcomes for Lung Adenocarcinoma with EGFR Germline Mutations. J Thorac Oncol 19(10):1438-1448, 2024. e-Pub 2024. PMID: 38866326.
- Zhang Bingnan, Komal Shah, Parma Mitchell, Wang Kaiwen, Singhi Eric, Lewis Whitney, Rivera Melvin, Altan Mehmet, Le Xiuning, Vokes Natalie, Fossella Frank, O'Brien Barbara, Wang Chenyang, Tom Martin, Beckham Thomas, Swanson Todd, Bronk Julianna, Lin Steven, Vega Maria, Jacome Joshua, Halliday Alexa, Negrao Marcelo, Zhang Jianjun, Gibbons Don, Heymach John, Byers Lauren, Gay Carl, Pozadzides Jenny. Brief Report: Rapid Intracranial Response with Tarlatamab in Patients with Untreated Brain Metastases from Small Cell Lung Cancer - A Real-world Case Series. e-Pub 2024.
- Joe CY, Lin SH, Liao Z, Gandhi S, Gay C, Zhang J, Chun S, Elamin Y, Fossella FV, Blumeinschein G, Cascone T, Le X, Pozadzides J, Tsao A, Yao L, Verma V, Welsh J, Chen A, Altan M, Mehran RJ, Vaporciyan A, Swisher S, Balter P, Wistuba I, Fujimoto J, Fen L, Heymach J, Lee J, Dong W. Nivolumab after Stereotactic Ablative Radiotherapy for Early-Stage non-small Cell Lung Cancer. J Thorac Onc 18(11):S71, 2023. e-Pub 2023.
- Wang K, Robyn D, Lewis WE, Hong L, Skoulidis F, Byers L, Tsao A, Cascone T, Tu J, Pozadzides J, Vailati Negrao M, Heymach J, Zhang J, Le X. Brief Report: Real-world Efficacy and Safety of Amivantamab for EGFR-mutant Non-small Cell Lung Cancer (NSCLC). J Thoracic Onc(D-23-01057R2), 2023. e-Pub 2023.
- Chang JY, Lin SH, Dong W, Liao Z, Gandhi SJ, Gay CM, Zhang J, Chun SG, Elamin YY, Fossella FV, Blumenschein G, Cascone T, Le X, Pozadzides JV, Tsao A, Verma V, Welsh JW, Chen AB, Altan M, Mehran RJ, Vaporciyan AA, Swisher SG, Balter PA, Fujimoto J, Wistuba II, Feng L, Lee JJ, Heymach JV. Stereotactic Ablative Radiotherapy with or without Immunotherapy for Early-Stage or Isolated Lung Parenchymal Recurrent Node-negative non-small-cell Lung Cancer: An open-label, randomized, Phase 2 Trial. Lancet 402(10405):871-881, 2023. e-Pub 2023. PMID: 37478883.
- Lewis DJ, Falck BA, Kantrow SM, Pozadzides JV, Hinojosa T, Huang S, Diwan AH, Prieto VG, Duvic M. Necrotizing Granulomatous Dermatitis and Panniculitis Masquerading as T Cell Lymphoma. Skinmed 17(6):406-408, 2019. e-Pub 2019. PMID: 31904333.
- Jahan-Tigh RR, Huen AO, Lee GL, Pozadzides JV, Liu P, Duvic M. Hydrochlorothiazide and Cutaneous T cell Lymphoma: Prospective analysis and case series. Cancer 119(4):825-31, 2013. e-Pub 2013. PMID: 22952039.
- Overman MJ, Pozadzides J, Kopetz S, Wen S, Abbruzzese JL, Wolff RA, Wang H. Immunophenotype and Molecular Characterisation of Adenocarcinoma of the Small Intestine. Br J Cancer 102(1):144-50, 2010. e-Pub 2010. PMID: 19935793.
- Talpur R, Vu J, Bassett R, Stevens V, Duvic M. Phase I/II Randomized Bilateral Half-Head Comparison of Topical Bexarotene 1% Gel for Alopecia Areata. J Am Acad Dermatol 61(4):592 e1-9, 2009. e-Pub 2009. PMID: 19682769.
- Vu J, Bangert S, Hebert A. Association of Pollo and Skin Cancer: A case study. Archives of Dermatology, 2007. e-Pub 2007.
- Vu J, Wallace GR, Singh R, Diwan H, Prieto V, Rady P, Tyring S, Duvic M. Common Variable Immunodeficiency Syndrome Associated with Epidermodysplasia Verruciformis. Am J Clin Dermatol 8(5):307-10, 2007. e-Pub 2007. PMID: 17902733.
- Weng JK, Negrao M, Lin R, Marqueen KE, Ning M, Chun SG, Pozadzides J, Williams R, Lin SH, Delclos M, Zhang J, Le X, Elamin Y, Lu C, Singhi E, Blumenschein G, Tsao A, Liao Z, Gandhi S, Nguyen Q, Chen A, O'Reilly M, Welsh J, Bronk J, Chang J, Heymach J, Lee P. Local Consolidative Therapy and Durvalumab for Oligometastatic Non-Small Cell Lung Cancer after Upfront Chemoradiation and Anti-PD-L1 Therapy for Stage III Disease: The ENDURE Trial. JAMA Onc.
Invited Articles
- Creed RD, Vu J, Duvic M. Alopecia Areata and Mycosis Fungoides: HLA Association. The Internet Journal of Dermatology(ISSN 1531-3018), 2012. e-Pub 2012.
- Pozadzides JV, Pro B. Hepatosplenic T-cell Lymphoma and TNF-α Inhibitors. Expert Rev Hematol 2(6):611-4, 2009. e-Pub 2009. PMID: 21082951.
- Duvic M, Vu J. Update on the Treatment of Cutaneous T-cell Lymphoma (CTCL): Focus on vorinostat. Biologics 1(4):377-92, 2007. e-Pub 2007. PMID: 19707308.
- Duvic M, Vu J. Vorinostat in Cutaneous T-cell Lymphoma. Drugs Today (Barc) 43(9):585-99, 2007. e-Pub 2007. PMID: 17940636.
- Duvic M, Vu J. Vorinostat: A New Oral Histone Deacetylase Inhibitor Approved for Cutaneous T-cell Lymphoma. Expert Opin Investig Drugs 16(7):1111-20, 2007. e-Pub 2007. PMID: 17594194.
Other Articles
- Vu Pozadzides J Clinical Activity of RET Tyrosine Kinase Inhibitor (TKI) plus Chemotherapy after Progression on a RET TKI in a RET Fusion-Positive Non-Small Cell Lung Cancer Real-World Cohort: A Brief Report. JTO Clin Res Rep.
- Vu Pozadzides J, Zhang B Real-World Experience of Tarlatamab in Extensive-Stage Small Cell Lung Carcinoma showed Promising Systemic and Intracranial Efficacy with Higher Neurologic Toxicity. JCO Precis Onc.
- Elamin YY, Heeke S, Negrao MV, Fossella FV, Byers LA, Zhang J, Gay CM, Tu J, Pozadzides JV, Tran H, Le X, Feng L, Blumenschein G, Tsao AS, Heymach JV Efficacy and Safety of Osimertinib in Combination with Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Non-Small Cell Lung Cancer: Results from a Phase 1b Clinical Trial. J Clin Oncol.
- Hu X, Park MD, Montégut L, Zhu B, Salehjahromi M, Zhang C, Vokes N, Qi Y, Li H, Soong BY, Aminu, Muhammad, Halasz L, Fujimoto J, Hong L, Heeke S, Moreira AL, Solis LM, Haymaker C, Velcheti V, Sterman DH, Pass HI, Samstein RM, Cheng C, Lee JJ, Wei Z, Godoy M, Antonoff M, Tran H, Lin SH, Chang J, Liao Z, Carter B, Tam A, Rajaram R, Ostrin E, Le X, Gay CM, Negrao MV, Byers L, Pozadzides JV, Chen H, Blumenschein G, Rice D, Walsh GL, Cascone T, Sepesi B, Hofstetter W, Mehran R, Vaporciyan A, Zhang B, Araujo H, Moghaddam S, Wang L, Davis MM, Dubinett SM, Lippman S, Spira A, Mantovani A, Wu Y, Wistuba II, Futreal AP, Zhong W, Reuben A, Wu J, Heymach JV, Merad M, Zhang JJ Myeloid IL-1 Signaling Drives the Precancer-to-Cancer Evolution of Human Pulmonary Nodules. Nature Med.
Abstracts
- Chang J, Lin S, Liao Z, Gandhi S, Chun S, Welsh J, Fossella F, Gay C, Zhan JJ, Blumenschein G, Cascone T, Xiuning L, Pozadzides J, Altan M, Tsao A, Heymach J, Le J, Wistuba I. Randomized Phase II Study Comparing Stereotactic Ablative Radiotherapy with or without Immunotherapy for Early-Stage or Isolated Parenchymal Recurrent Non-Small Cell Lung Cancer: I-SABR Trial. American Society of Clinical Oncology (ASCO), 2023. e-Pub 2023.
- Du R, Elamin Y, Lewis W, Hong L, Spelman A, Skoulidis F, Byers L, Tsao A, Cascone T, Pozadzides J, Tu J, Negrao M, Zhang J, Heymach J, Le X. Efficacy of Amivantamab as a Next Line Therapy for EGFR-mutant Non-small Cell Lung Cancer. American Society of Clinical Oncology (ASCO), 2022. e-Pub 2022.
- Elamin Y, Negrao M, Fossella F, Byers L, Zhang J, Gay C, Tu J, Pozadzides J, Tran H, Lu C, Feng L, Spelman A, Blumenschein G, Tsao A, Heymach J. Results of a Phase 1B Study of Osimertinib plus Alisertib or Sapanisertib for Osimertinib-resistant EGFR Mutant Non-small Cell Lung Cancer. (NSCLC). American Society of Clinical Oncology (ASCO), 2022. e-Pub 2022.
- Aminu M, Vokes N, Saad M, Li H, Hong L, Mohamed M, Boom J, Chen P, Altan M, Gandhi S, Swisher S, Antonoff M, Pozadzides J, Blumenschein G, Gibbons D, Cascone T, Elamin Y, Le X, Negrao M, Skoulidis F, Tsao A, Tu J, Lee J, Zhang JJ, Heymach J, Wu J. Tumor Volumetric Analysis to Correlate Disease Burden with Response to Dual Immune Checkpoint Blockade in Metastatic. (NSCLC). American Association of Cancer Research, 2022. e-Pub 2022.
- Pozadzides J, Keating M, Wierda W, O'Brien S, Burger J, JOrgensen J, Calin S, Wang SA, Loerner S, Ferrajoli. Initial Experience with Lenalidomide as Consolidation Treatment in Patients with Chronic Lymphocytic Leukemia and Residual Disease after Chemotherapy. American Society of Hematology (ASH), 2011. e-Pub 2011.
- Pozadzides J. Association of Polio and Skin Cancer, 65th Annual Meeting, Washington DC. American Academy of Dermatology, 2007. e-Pub 2007.
- Pozadzides J. Dermatofibromas in a Patient of Mycosis Fungoides-Are They Related in Immunosuppression, 43rd Annual Meeting, Chicago, Illinois. The American Society of Dermatopathology, 2006. e-Pub 2006.
- Pozadzides J. Necrotizing Granulomatous Dermatitis and Panniculities Masquerading as T-Cell Lymphoma 43rd Annual Meeting, Chicago, Illinois. The American Society of Dermatopathology, 2006. e-Pub 2006.
- Aminu M, Zhu B, Saad M, Li H, Hong L, Mohamed MQ, Altan M, Gandhi S, Solis Soto LM, Shi O, Rojas FR, Santiago Treviño III, Burns B, Swisher SG, Antonoff MB, Pozadzides JV, Blumenschein G Jr, Gibbons DL, Cascone T, Elamin YY, Le X, Negrao MV, Skoulidis F, Tsao A, Tu J, Lee J, Wu J, Zhang J, Heymach JV, Vokes NI. Immune Cell Infiltration and Spatial Associations in the Tumor Microenvironment Following Dual Immune Checkpoint Inhibition or ICI-Chemotherapy. 2025 World Conference on Lung Cancer.
- Zhang J, Zhu B, Salehjahromi M, Heeke S, Godoy M, Vokes N, Tran H, Lin SH, Carter B, Tam A, Rajaram R, Antonoff M, Ostrin E, Le X, Gay C, Negrao MV, Byers L, Pozadzides JV, Chen H, Blumenschein G, Rice D, Walsh GL, Cascone T, Sepesi B, Hofstetter W, Mehran R, Wu C, Vaporciyan A, Zhang B, Araujo H, Moghaddam S, Wistuba I, Lee J, Wu J, Heymach JV. Can-Prevent-Lung Precancer Interception Trial and Preclinical Studies Reveal Stage-dependent Biology in Lung Cancer and Precancers. 2025 European Society for Medical Oncology (ESMO).
Book Chapters
- Pozadzides J, Duvic M, Pro B. T-Cell Lymphomas. In: The MD Anderson 2nd Edition of the Manual of Medical Oncology, 2010.
Patient Reviews
CV information above last modified July 22, 2026